Product1 publisher3 min readPublished
Weave sells itself to Francisco Partners for $650M, about 2.7 times revenue
A 34 percent premium still prices a company growing 17 percent at under three times sales. Independent practices should read the AI-and-payments roadmap as a pricing plan.
The Product Desk · Product desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- Weave Communications said it will exit the public markets after agreeing to be acquired for $650 million by private equity firm Francisco Partners in an all-cash deal.
- Weave shareholders will receive $7.40 per share, a premium of around 34 percent to Weave's closing stock price on August 17.
- Weave will delist from the New York Stock Exchange, where it has traded under the ticker WEAV since going public in 2021, when the deal closes.
- Founded in 2008, Weave makes a patient communication platform for independent medical, dental, optometry and veterinary practices, used to send patient communications, schedule appointments and process payments.
- According to Chief Executive Brett White, Weave's customer base is a category most software companies overlook.
Compiled by The Product DeskSomething wrong?How this is made
Why it matters
Weave Communications agreed to be acquired by Francisco Partners for $650 million in an all-cash deal, with shareholders receiving $7.40 a share, a premium of roughly 34 percent to the August 17 close [1][2]. The premium is not the interesting number: $650 million against $239 million of fiscal 2025 revenue is about 2.7 times sales for a business that grew 17 percent [8][1].
Weave sells patient communication, scheduling and payments software to independent medical, dental, optometry and veterinary practices, a customer base its chief executive Brett White has described as one most software companies overlook [4][5]. The operating numbers are not the problem. Fiscal 2025 revenue was $239 million, up 17 percent, and first-quarter fiscal 2026 revenue was $65.5 million, also up 17 percent year over year [8][9], which annualizes to roughly $262 million and puts the deal at about 2.5 times a forward run rate [2].
The public market valuation is the problem. Weave closed at $7.28 after a 32 percent jump on the announcement, and even with that move it was down 4 percent year to date and more than 8 percent over twelve months [10][11]. Its all-time high after the November 2021 IPO was $22.40, so the take-private price is about 67 percent below the peak, and the $650 million headline is roughly 46 percent of the $1.4 billion market cap Weave once carried [11][3][6]. SiliconANGLE attributes part of that derating to investor fear of an AI-driven "SaaSpocalypse," in which cheap software generation erodes subscription businesses [16]. Note also that the $582.5 million market cap at $7.28 implies about 80 million shares, worth roughly $592 million at $7.40, so the $650 million figure includes something beyond basic equity [11][5].
What happens next is written into the stated plan. White said the deal will let Weave invest in its AI platform and deepen its payments and revenue cycle management capabilities [6], and Weave has already bought TrueLark, an AI front-desk automation startup, to extend agentic AI to multi-location practices [7]. Payments and revenue cycle work are take-rate businesses rather than seat businesses. That is the most plausible route to growing a $239 million revenue base faster than you can add independent practices, and it is a route that runs through existing customers' invoices rather than new logos.
Francisco Partners has raised more than $75 billion since 1999 and invested in over 500 technology companies, including healthcare software [12]. It bought practice management vendor AdvancedMD for $1.125 billion in November 2024, about 1.7 times what it is paying for Weave [13][7]. Co-President Ezra Perlman described Weave's position at the center of how tens of thousands of practices communicate with patients and collect revenue as "difficult to build and harder still to replicate" [14]. That is a description of switching costs, which is also the precondition for raising prices.
The board approved unanimously, and the deal still needs shareholder approval and regulatory clearance, with closing expected before the end of the year [15]. Watch for shareholder objections to a 34 percent premium struck 67 percent below the high [2][3]; watch whether Weave and AdvancedMD are packaged together [13]; and watch the first renewal cycle after close for bundled AI receptionist and payments pricing.